|
1) Chen J, Gu D, Chen CS, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007; 22: 1100-6
|
|
|
|
2) Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16: 2134-40
|
|
|
|
|
|
3) Ninomiya T, Kiyohara Y, Kubo M, et al. Meta-bolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006; 48: 383-91
|
|
|
|
|
|
4) Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006; 69: 369-74
|
|
|
|
|
|
5) Frederich RC Jr, Kahn BB, Peach MJ, et al. Tissue-specific nutritional regulation of angio-tensinogen in adipose tissue. Hypertension. 1992; 19: 339-44
|
|
|
|
|
|
6) Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome？ Int J Biochem Cell Biol. 2003; 35: 807-25
|
|
|
|
|
|
7) Kurata A, Nishizawa H, Kihara S, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006; 70: 1717-24
|
|
|
|
|
|
8) Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006; 17: 2999-3012
|
|
|
|
|
|
9) Krag S, Danielsen CC, Carmeliet P, et al. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int. 2005; 68: 2651-66
|
|
|
|
|
|
10) Zhang G, Kernan KA, Collins SJ, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol. 2007; 18: 846-59
|
|
|
|
|
|
11) Edgtton KL, Gow RM, Kelly DJ, et al. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int. 2004; 66: 68-76
|
|
|
|
|
|
12) Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100: 2473-6
|
|
|
|
|
|
13) Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103: 1057-63
|
|
|
|
|
|
14) Zoccali C, Mallamaci F, Panuccio V, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int. 2003: S98-102
|
|
|
|
|
|
15) Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006; 98: 1603-8
|
|
|
|
|
|
16) Shen YY, Charlesworth JA, Kelly JJ, et al. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant. 2007; 22: 171-8
|
|
|
|
|
|
17) Zoccali C, Mallamaci F, Tripepi G, et al. Adipo-nectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 134-41
|
|
|
|
|
|
18) Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16: 1091-8
|
|
|
|
|
|
19) Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2599-606
|
|
|
|
|
|
20) Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol. 2007; 27: 1910-7
|
|
|
|
|
|
21) Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91
|
|
|
|
|
|
22) Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-30
|
|
|
|
|
|
23) Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-808
|
|
|
|
|
|
24) de Vinuesa SG, Goicoechea M, Kanter J, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J Am Soc Nephrol. 2006; 17(12 Suppl 3): S206-12
|
|
|
|
|
|
25) Ishaque A, Dunn MJ, Sorokin A. Cyclo-oxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem. 2003; 278: 10629-40
|
|
|
|
|
|
26) Guo G, Morrissey J, McCracken R, et al. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol. 2001; 280: F777-85
|
|
|
|
|
|
27) Nordfors L, Lonnqvist F, Heimburger O, et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int. 1998; 54: 1267-75
|
|
|
|
|
|
28) Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int. 1999; 56: 860-72
|
|
|
|
|